Cargando…

Site‐specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival

Detalles Bibliográficos
Autores principales:	Gangat, Naseema, Singh, Amritpal, Szuber, Natasha, Begna, Kebede, Elliott, Michelle, Wolanskyj‐Spinner, Alexandra, Hanson, Curtis A., Pardanani, Animesh, De Stefano, Valerio, Barbui, Tiziano, Vannucchi, Alessandro M., Tefferi, Ayalew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804406/ https://www.ncbi.nlm.nih.gov/pubmed/35894106 http://dx.doi.org/10.1111/jth.15834

Ejemplares similares

1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events
por: Gangat, Naseema, et al.
Publicado: (2022)

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
por: Gangat, Naseema, et al.
Publicado: (2022)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

MPL-mutated essential thrombocythemia: a morphologic reappraisal
por: Szuber, Natasha, et al.
Publicado: (2018)

JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
por: Gangat, Naseema, et al.
Publicado: (2021)

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates
por: Szuber, Natasha, et al.
Publicado: (2018)

Essential thrombocythemia treatment algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2023)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis
por: Mudireddy, Mythri, et al.
Publicado: (2018)

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
por: Gangat, Naseema, et al.
Publicado: (2021)

The new WHO classification for essential thrombocythemia calls for revision of available evidences
por: Barbui, Tiziano, et al.
Publicado: (2020)

Genetic predictors of response to specific drugs in primary myelofibrosis
por: Penna, Domenico, et al.
Publicado: (2018)

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
por: Nicolosi, Maura, et al.
Publicado: (2018)

Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates
por: Shah, Sahrish, et al.
Publicado: (2017)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
por: Vallapureddy, Rangit R., et al.
Publicado: (2019)

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

Momelotinib therapy for myelofibrosis: a 7-year follow-up
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
por: Begna, Kebede H., et al.
Publicado: (2021)

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
por: Tefferi, Ayalew, et al.
Publicado: (2018)

CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival
por: Szuber, Natasha, et al.
Publicado: (2018)

The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study
por: Liu, Qiuju, et al.
Publicado: (2021)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
por: Abdelmagid, Maymona G., et al.
Publicado: (2022)

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
por: Tefferi, A, et al.
Publicado: (2017)

A population-based study of chronic neutrophilic leukemia in the United States
por: Ruan, Gordon J., et al.
Publicado: (2020)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
por: Gangat, Naseema, et al.
Publicado: (2020)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
por: Gangat, Naseema, et al.
Publicado: (2019)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
por: Barbui, T, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7ngn9cqtgu83m5d1gg5ejafq3m